MedTrace Logo

Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies

NCT01256905 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2021-08-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate if a drug commonly used to treat excessive day-time sleepiness, called armodafinil (Nuvigil), is also effective in improving the impairment in the attention commonly reported by patients with more advanced Parkinson's disease (PD) and Lewy body disease (LBD).

Conditions

  • Parkinsons Disease
  • Lewy Bodies Disease

Interventions

DRUG

Armodafinil

Armodafinil 150 mg

Sponsors & Collaborators

Principal Investigators

  • Sara Varanese, MD · NYU Parkinsons and Movement Disorders Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-01
Primary Completion
2011-08-08
Completion
2011-08-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01256905 on ClinicalTrials.gov